Why invest

A solid platform with unique business model 

• Leading market positions – Largest pharma company in MENA¹, 7th largest generic pharma company in US², Sixth largest generic injectable supplier in Europe³
• Expanding manufacturing footprint - 29 plants across our markets, with additional facilities being established
• Global player with local expertise
• Trusted partner known for our commitment to quality and reliability of supply
• Agile supply chain, flexible manufacturing and leading technical capabilities

An increasingly diverse portfolio and pipeline

• A broad portfolio that is tailored to local market needs
• Growing presence in specialty, complex and higher-value products, which offer less competition and higher margins
• Strong momentum in new product launches across our markets
• Enhancing our pipeline by adding innovative products through value-creating partnerships
• Adding to the strength of our base business through strategic acquisitions

Strategic execution driven by our three pillars

A proven track record of delivery for shareholders

• Group revenue compound annual growth rate (CAGR) of  7% and core EBIT CAGR of 6% since 2020
• Strong cash generation with $436m operating cash flow in 2025
• Strong balance sheet that provides financial flexibility to support future growth, with low leverage of 1.6x net debt to EBITDA
• High returns, with 16.0% return on average invested capital